24-hour Efficacy of AR-12286

Phase 2

Completed

• Conditions: Open Angle Glaucoma; Ocular Hypertension

• Registration Number: NCT01330979
• Lead Sponsor: Aerie Pharmaceuticals

Brief Summary

An open-label, non-comparative, pilot evaluation of the 24-hour ocular hypotensive efficacy of AR-12286 in patients with open-angle glaucoma or ocular hypertension

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-04-06
• Study First Submitted QC: 2011-04-06
• Study First Posted: 2011-04-07
• Study Start: 2011-05
• Primary Completion: 2012-08
• Study Completion: 2012-08
• Disposition First Submitted: 2014-02-17
• Status Verified: 2014-03
• Disposition First Submitted QC: 2014-03-25
• Last Update Submitted: 2014-03-25
• Disposition First Posted: 2014-04-21
• Last Update Posted: 2014-04-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Intraocular pressure	Day 28	Intraocular pressure compared to baseline

Secondary Outcome Measures

Name	Time	Method
Intraocular pressure	Day 28	Diurnal IOP

Trial Locations

Locations (1)

University of California; 🇺🇸 San Diego, California, United States